Collplant Biotechnologies Ltd (CLGN) Stock Analysis

AI analysis of Collplant Biotechnologies Ltd (CLGN)

Hold

CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.

Valuation Metrics

The current forward P/E ratio for Collplant Biotechnologies Ltd (CLGN) is 80.00, compared to its 5-year average forward P/E of 16.78.

Forward P/E

Overvalued

5Y Average P/E

16.78

Current P/E

80.00

Overvalued

65.92

Undervalued

-32.36

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

-0.00

Current EV/EBITDA

-0.06

Overvalued

0.01

Undervalued

-0.02

Forward P/S

Fair

5Y Average P/S

54.13

Current P/S

1.60

Overvalued

167.70

Undervalued

-59.44

Alphio AI Price Scenarios for CLGN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CLGN

$10.06

Scenario price

B

Base

Base · 50%CLGN

$9.13

Scenario price

B

Bear

Bear · 25%CLGN

$6.57

Scenario price

CLGN FAQ — answered by Alphio AI

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen). It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

CollPlant Biotechnologies Ltd is not a strong buy right now due to its current price of $3.97, which is significantly below its 52-week high of $22.50, indicating a potential for recovery but also high risk. The company has a forward P/E ratio of 80, suggesting that it is highly valued relative to its earnings, which are currently negative. Additionally, the RSI is at 47.809, indicating a neutral momentum, and the stock has experienced a year-to-date change of -73.18%, reflecting ongoing challenges. The main risk is its high volatility, with an implied volatility of 671.43%, which could lead to significant price swings.